Publication Author: Basu_Anirban

• Heterogeneity in action: the role of passive personalization in comparative effectiveness research.

  Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: the role of passive personalization in comparative effectiveness research. Health Econ. 2014 Mar;23(3):359-73. doi: 10.1002/hec.2996. Epub 2013 Oct 9.

  rakerr2

  March 1, 2014

• Response to Epstein’s comment on “heterogeneity in action”.

  Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Response to Epstein’s comment on “heterogeneity in action”. Health Econ. 2014 Mar;23(3):376-8. doi: 10.1002/hec.3031. Epub 2014 Jan 21.

  rakerr2

  March 1, 2014

• Risk stratification for sudden cardiac death: a plan for the future.

  Goldberger JJ, Basu A, Boineau R, Buxton AE, Cain ME, Canty JM Jr, Chen PS, Chugh SS, Costantini O, Exner DV, Kadish AH, Lee B, Lloyd-Jones D, Moss AJ, Myerburg RJ, Olgin JE, Passman R, Stevenson WG, Tomaselli GF, Zareba W, Zipes DP, Zoloth L. Risk strati

  rakerr2

  January 28, 2014

• Personalized Medicine in the Context of Comparative Effectiveness Research.

  Basu A. Personalized Medicine in the Context of Comparative Effectiveness Research. Forum Health Econ Policy. 2013 Sep 1;16(2):S73-S86. doi: 10.1515/fhep-2013-0009.

  rakerr2

  September 1, 2013

• Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed.

  Basu A. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed. Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):163-5. doi: 10.1586/erp.13.8.

  rakerr2

  April 1, 2013

• Patient-centered or ‘central’ patient: Raising the veil of ignorance over randomization.

  Basu A. Patient-centered or ‘central’ patient: Raising the veil of ignorance over randomization. Stat Med. 2012 Nov 10;31(25):3057-9. doi: 10.1002/sim.5398.

  rakerr2

  November 10, 2012

• Private manufacturers’ thresholds to invest in comparative effectiveness trials.

  Basu A, Meltzer D. Private manufacturers’ thresholds to invest in comparative effectiveness trials. Pharmacoeconomics. 2012 Oct 1;30(10):859-68. doi: 10.2165/11597730-000000000-00000.

  rakerr2

  October 1, 2012

• Systematizing the Use of Value of Information Analysis in Prioritizing Systematic Reviews

  Hoomans T, Seidenfeld J, Basu A, Meltzer D. Systematizing the Use of Value of Information Analysis in Prioritizing Systematic Reviews [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. Available from http://www.ncbi.nlm

  rakerr2

  September 1, 2012

• Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs.

  Basu A, Meltzer HY. Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. J Comp Eff Res. 2012 Mar;1(2):171-80. doi: 10.2217/cer.12.8.

  rakerr2

  March 1, 2012

• Comparative cost analysis of housing and case management program for chronically ill homeless adults compared to usual care.

  Basu A, Kee R, Buchanan D, Sadowski LS. Comparative cost analysis of housing and case management program for chronically ill homeless adults compared to usual care. Health Serv Res. 2012 Feb;47(1 Pt 2):523-43. doi: 10.1111/j.1475-6773.2011.01350.x. Epub 2

  rakerr2

  February 1, 2012